Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Laurent-Puig

Showing results (1-10 of 405) with videos related to

Pageof 41
Sort By:
Medecine Sciences : M/S|April 14, 2009
[Biological criteria of eligibility for a treatment against EGFR]Pierre Laurent-Puig
Human Mutation|March 6, 2003
TP53 and head and neck neoplasmsHélène Blons, Pierre Laurent-Puig
Personalized Medicine|May 24, 2018
Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodiesAstrid Lièvre, Pierre Laurent-Puig
La Revue Du Praticien|January 5, 2011
[Biology applied to cancer treatments: the example of colorectal cancer]Astrid Lièvre, Pierre Laurent-Puig
Nature Reviews. Clinical Oncology|June 6, 2013
Surgery: Cetuximab--an option for unresectable CRC liver metastasesPierre Laurent-Puig, Leonor Benhaim
Bulletin Du Cancer|January 31, 2008
[Predictive factors of response to anti-EGFR treatments in colorectal cancer]Astrid Lièvre, Pierre Laurent-Puig
La Revue Du Praticien|April 17, 2004
[Colorectal carcinogenesis: update]Astrid Lièvre, Pierre Laurent-Puig
La Revue Du Praticien|August 22, 2008
[Prophylactic colectomy in hereditary colorectal cancer]Bruno Buecher, Pierre Laurent-Puig
Nature Reviews. Clinical Oncology|June 2, 2009
Genetics: Predictive value of KRAS mutations in chemoresistant CRCAstrid Lièvre, Pierre Laurent-Puig
Gastroenterologie Clinique Et Biologique|March 2, 2005
[Mitochondrial DNA mutations and colorectal cancer]Astrid Lièvre, Pierre Laurent-Puig
Pageof 41

Showing results (1-10 of 405) with videos related to

Sort By:
Pageof 41
Medecine Sciences : M/S|April 14, 2009
[Biological criteria of eligibility for a treatment against EGFR]Pierre Laurent-Puig
Human Mutation|March 6, 2003
TP53 and head and neck neoplasmsHélène Blons, Pierre Laurent-Puig
Personalized Medicine|May 24, 2018
Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodiesAstrid Lièvre, Pierre Laurent-Puig
La Revue Du Praticien|January 5, 2011
[Biology applied to cancer treatments: the example of colorectal cancer]Astrid Lièvre, Pierre Laurent-Puig
Nature Reviews. Clinical Oncology|June 6, 2013
Surgery: Cetuximab--an option for unresectable CRC liver metastasesPierre Laurent-Puig, Leonor Benhaim
Bulletin Du Cancer|January 31, 2008
[Predictive factors of response to anti-EGFR treatments in colorectal cancer]Astrid Lièvre, Pierre Laurent-Puig
La Revue Du Praticien|April 17, 2004
[Colorectal carcinogenesis: update]Astrid Lièvre, Pierre Laurent-Puig
La Revue Du Praticien|August 22, 2008
[Prophylactic colectomy in hereditary colorectal cancer]Bruno Buecher, Pierre Laurent-Puig
Nature Reviews. Clinical Oncology|June 2, 2009
Genetics: Predictive value of KRAS mutations in chemoresistant CRCAstrid Lièvre, Pierre Laurent-Puig
Gastroenterologie Clinique Et Biologique|March 2, 2005
[Mitochondrial DNA mutations and colorectal cancer]Astrid Lièvre, Pierre Laurent-Puig
Pageof 41